Clinical Trial Update: Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of Omr-IgG-am for West Nile Virus disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• West Nile Virus

Drugs mentioned

• Omr-IgG-am

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: West Nile Virus | Phase 2 | Status: COMPLETED